Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals | Practical Law
This Practice Note discusses some key issues to consider when structuring and negotiating an option to acquire a pharmaceutical company, such as purchase price, duration of the option, events triggering the option, the relevant product's development plan and antitrust and accounting implications.